View in EDS HTML Full Text PDF Full Text

Pyrotinib inhibits the tumorigenicity of HER2-positive non-small cell lung cancer by inducing ARIH1/ubiquitin/lysosome-dependent degradation of HER2.

Saved in:
Bibliographic Details
Title: Pyrotinib inhibits the tumorigenicity of HER2-positive non-small cell lung cancer by inducing ARIH1/ubiquitin/lysosome-dependent degradation of HER2.
Authors: Li X; NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Jiangsu Province, China.; Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu Province, China.; Department of Respiratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, 214000, Jiangsu Province, China.; Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China., Wang J; NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Jiangsu Province, China.; Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu Province, China.; Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China., Li S; NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Jiangsu Province, China.; Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu Province, China.; Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China., Fang J; NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Jiangsu Province, China.; Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China., Hao Y; Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, Jiangsu Province, China., Xu C; Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang Province, China., Shu Y; Department of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Province, China., Shu H; Department of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Province, China., Chen J; Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu Province, China.; Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China., Lu N; School of Food Science and Technology, Jiangnan University, Wuxi, 214122, Jiangsu Province, China., Zhu X; NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Jiangsu Province, China. zhuxue@jsinm.org.; Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China. zhuxue@jsinm.org., Wang K; NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Jiangsu Province, China. wangke@jsinm.org.; Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China. wangke@jsinm.org., Wang X; Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu Province, China. 081104125@fudan.edu.cn.; Department of Respiratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, 214000, Jiangsu Province, China. 081104125@fudan.edu.cn.
Source: Cellular oncology (Dordrecht, Netherlands) [Cell Oncol (Dordr)] 2025 Dec; Vol. 48 (6), pp. 1795-1808. Date of Electronic Publication: 2025 Oct 22.
Publication Type: Journal Article
Journal Info: Publisher: Springer Country of Publication: Netherlands NLM ID: 101552938 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-3436 (Electronic) Linking ISSN: 22113428 NLM ISO Abbreviation: Cell Oncol (Dordr) Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41123818
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pyrotinib inhibits the tumorigenicity of HER2-positive non-small cell lung cancer by inducing ARIH1/ubiquitin/lysosome-dependent degradation of HER2.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Li+X%22">Li X</searchLink>; NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Jiangsu Province, China.; Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu Province, China.; Department of Respiratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, 214000, Jiangsu Province, China.; Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Jiangsu Province, China.; Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu Province, China.; Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China.<br /><searchLink fieldCode="AU" term="%22Li+S%22">Li S</searchLink>; NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Jiangsu Province, China.; Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu Province, China.; Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China.<br /><searchLink fieldCode="AU" term="%22Fang+J%22">Fang J</searchLink>; NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Jiangsu Province, China.; Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China.<br /><searchLink fieldCode="AU" term="%22Hao+Y%22">Hao Y</searchLink>; Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, Jiangsu Province, China.<br /><searchLink fieldCode="AU" term="%22Xu+C%22">Xu C</searchLink>; Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang Province, China.<br /><searchLink fieldCode="AU" term="%22Shu+Y%22">Shu Y</searchLink>; Department of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Province, China.<br /><searchLink fieldCode="AU" term="%22Shu+H%22">Shu H</searchLink>; Department of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Province, China.<br /><searchLink fieldCode="AU" term="%22Chen+J%22">Chen J</searchLink>; Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu Province, China.; Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China.<br /><searchLink fieldCode="AU" term="%22Lu+N%22">Lu N</searchLink>; School of Food Science and Technology, Jiangnan University, Wuxi, 214122, Jiangsu Province, China.<br /><searchLink fieldCode="AU" term="%22Zhu+X%22">Zhu X</searchLink>; NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Jiangsu Province, China. zhuxue@jsinm.org.; Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China. zhuxue@jsinm.org.<br /><searchLink fieldCode="AU" term="%22Wang+K%22">Wang K</searchLink>; NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Jiangsu Province, China. wangke@jsinm.org.; Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China. wangke@jsinm.org.<br /><searchLink fieldCode="AU" term="%22Wang+X%22">Wang X</searchLink>; Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, Jiangsu Province, China. 081104125@fudan.edu.cn.; Department of Respiratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, 214000, Jiangsu Province, China. 081104125@fudan.edu.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101552938%22">Cellular oncology (Dordrecht, Netherlands)</searchLink> [Cell Oncol (Dordr)] 2025 Dec; Vol. 48 (6), pp. 1795-1808. <i>Date of Electronic Publication: </i>2025 Oct 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>101552938 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2211-3436 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222113428%22">22113428 </searchLink><i>NLM ISO Abbreviation: </i>Cell Oncol (Dordr) <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41123818
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s13402-025-01107-z
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1795
    Titles:
      – TitleFull: Pyrotinib inhibits the tumorigenicity of HER2-positive non-small cell lung cancer by inducing ARIH1/ubiquitin/lysosome-dependent degradation of HER2.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Li X
      – PersonEntity:
          Name:
            NameFull: Wang J
      – PersonEntity:
          Name:
            NameFull: Li S
      – PersonEntity:
          Name:
            NameFull: Fang J
      – PersonEntity:
          Name:
            NameFull: Hao Y
      – PersonEntity:
          Name:
            NameFull: Xu C
      – PersonEntity:
          Name:
            NameFull: Shu Y
      – PersonEntity:
          Name:
            NameFull: Shu H
      – PersonEntity:
          Name:
            NameFull: Chen J
      – PersonEntity:
          Name:
            NameFull: Lu N
      – PersonEntity:
          Name:
            NameFull: Zhu X
      – PersonEntity:
          Name:
            NameFull: Wang K
      – PersonEntity:
          Name:
            NameFull: Wang X
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2211-3436
          Numbering:
            – Type: volume
              Value: 48
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Cellular oncology (Dordrecht, Netherlands)
              Type: main
ResultId 1